Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 106

1.

Comparison of Proximal Femur and Vertebral Body Strength Improvements in the FREEDOM Trial Using an Alternative Finite Element Methodology.

Zysset P, Pahr D, Engelke K, Genant HK, McClung MR, Kendler DL, Recknor C, Kinzl M, Schwiedrzik J, Museyko O, Wang A, Libanati C.

Bone. 2015 Jun 30. pii: S8756-3282(15)00262-8. doi: 10.1016/j.bone.2015.06.025. [Epub ahead of print]

PMID:
26141837
2.

Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years.

Ferrari S, Adachi JD, Lippuner K, Zapalowski C, Miller PD, Reginster JY, Törring O, Kendler DL, Daizadeh NS, Wang A, O'Malley CD, Wagman RB, Libanati C, Lewiecki EM.

Osteoporos Int. 2015 Jun 12. [Epub ahead of print]

PMID:
26068295
3.

Treatment with denosumab reduces secondary fracture risk in women with postmenopausal osteoporosis.

Palacios S, Kalouche-Khalil L, Rizzoli R, Zapalowski C, Resc H, Adachi JD, Gallagher JC, Feldman RG, Kendler DL, Wang A, Wagman RB, Adami S.

Climacteric. 2015 Jun 1:1-23. [Epub ahead of print]

PMID:
26029985
4.

A case report of osteomalacia unmasking primary biliary cirrhosis.

Pawlowska M, Kapeluto JE, Kendler DL.

Osteoporos Int. 2015 Jul;26(7):2035-8. doi: 10.1007/s00198-015-3102-5. Epub 2015 Mar 24.

PMID:
25801184
5.

A 24-month study evaluating the efficacy and safety of denosumab for the treatment of men with low bone mineral density: results from the ADAMO trial.

Langdahl BL, Teglbjærg CS, Ho PR, Chapurlat R, Czerwinski E, Kendler DL, Reginster JY, Kivitz A, Lewiecki EM, Miller PD, Bolognese MA, McClung MR, Bone HG, Ljunggren Ö, Abrahamsen B, Gruntmanis U, Yang YC, Wagman RB, Mirza F, Siddhanti S, Orwoll E.

J Clin Endocrinol Metab. 2015 Apr;100(4):1335-42. doi: 10.1210/jc.2014-4079. Epub 2015 Jan 21.

PMID:
25607608
6.

Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus.

Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK, O'Ryan F, Reid IR, Ruggiero SL, Taguchi A, Tetradis S, Watts NB, Brandi ML, Peters E, Guise T, Eastell R, Cheung AM, Morin SN, Masri B, Cooper C, Morgan SL, Obermayer-Pietsch B, Langdahl BL, Al Dabagh R, Davison KS, Kendler DL, Sándor GK, Josse RG, Bhandari M, El Rabbany M, Pierroz DD, Sulimani R, Saunders DP, Brown JP, Compston J; International Task Force on Osteonecrosis of the Jaw.

J Bone Miner Res. 2015 Jan;30(1):3-23. doi: 10.1002/jbmr.2405.

PMID:
25414052
7.

Persistence at 12 months with denosumab in postmenopausal women with osteoporosis: interim results from a prospective observational study.

Silverman SL, Siris E, Kendler DL, Belazi D, Brown JP, Gold DT, Lewiecki EM, Papaioannou A, Simonelli C, Ferreira I, Balasubramanian A, Dakin P, Ho P, Siddhanti S, Stolshek B, Recknor C.

Osteoporos Int. 2015 Jan;26(1):361-72. doi: 10.1007/s00198-014-2871-6. Epub 2014 Sep 19.

8.

Assessing the Effects of Teriparatide Treatment on Bone Mineral Density, Bone Microarchitecture, and Bone Strength.

Kleerekoper M, Greenspan SL, Lewiecki EM, Miller PD, Kendler DL, Maricic M, Keaveny TM, Kopperdahl DL, Ruff VA, Wan X, Janos B, Krohn K.

J Bone Joint Surg Am. 2014 Jun 4;96(11):e90. [Epub ahead of print]

PMID:
24897747
9.

Build better bones with exercise: protocol for a feasibility study of a multicenter randomized controlled trial of 12 months of home exercise in women with a vertebral fracture.

Giangregorio LM, Thabane L, Adachi JD, Ashe MC, Bleakney RR, Braun EA, Cheung AM, Fraser LA, Gibbs JC, Hill KD, Hodsman AB, Kendler DL, Mittmann N, Prasad S, Scherer SC, Wark JD, Papaioannou A.

Phys Ther. 2014 Sep;94(9):1337-52. doi: 10.2522/ptj.20130625. Epub 2014 May 1.

10.

Fibroblast growth factor 23 is elevated in tenofovir-related hypophosphatemia.

Saeedi R, Jiang SY, Holmes DT, Kendler DL.

Calcif Tissue Int. 2014 Jun;94(6):665-8. doi: 10.1007/s00223-014-9854-7. Epub 2014 Apr 5.

PMID:
24706031
11.

Understanding and communicating the benefits and risks of denosumab, raloxifene, and teriparatide for the treatment of osteoporosis.

Lewiecki EM, Miller PD, Harris ST, Bauer DC, Davison KS, Dian L, Hanley DA, McClung MR, Yuen CK, Kendler DL.

J Clin Densitom. 2014 Oct-Dec;17(4):490-5. doi: 10.1016/j.jocd.2013.09.018. Epub 2013 Oct 25. Review.

PMID:
24206867
12.

The Official Positions of the International Society for Clinical Densitometry: Indications of Use and Reporting of DXA for Body Composition.

Kendler DL, Borges JL, Fielding RA, Itabashi A, Krueger D, Mulligan K, Camargos BM, Sabowitz B, Wu CH, Yu EW, Shepherd J.

J Clin Densitom. 2013 Oct-Dec;16(4):496-507. doi: 10.1016/j.jocd.2013.08.020. Epub 2013 Oct 16. Review.

PMID:
24090645
13.

The generalized bone phenotype in children with neurofibromatosis 1: a sibling matched case-control study.

Armstrong L, Jett K, Birch P, Kendler DL, McKay H, Tsang E, Stevenson DA, Hanley DA, Egeli D, Burrows M, Friedman JM.

Am J Med Genet A. 2013 Jul;161A(7):1654-61. doi: 10.1002/ajmg.a.36001. Epub 2013 May 25.

PMID:
23713011
14.

Influence of patient perceptions and preferences for osteoporosis medication on adherence behavior in the Denosumab Adherence Preference Satisfaction study.

Kendler DL, Macarios D, Lillestol MJ, Moffett A, Satram-Hoang S, Huang J, Kaur P, Tang ET, Wagman RB, Horne R.

Menopause. 2014 Jan;21(1):25-32. doi: 10.1097/GME.0b013e31828f5e5d.

PMID:
23676636
15.

High-resolution peripheral quantitative computed tomography for the assessment of bone strength and structure: a review by the Canadian Bone Strength Working Group.

Cheung AM, Adachi JD, Hanley DA, Kendler DL, Davison KS, Josse R, Brown JP, Ste-Marie LG, Kremer R, Erlandson MC, Dian L, Burghardt AJ, Boyd SK.

Curr Osteoporos Rep. 2013 Jun;11(2):136-46. doi: 10.1007/s11914-013-0140-9. Review.

16.

Approaches to treating NF1 tibial pseudarthrosis: consensus from the Children's Tumor Foundation NF1 Bone Abnormalities Consortium.

Stevenson DA, Little D, Armstrong L, Crawford AH, Eastwood D, Friedman JM, Greggi T, Gutierrez G, Hunter-Schaedle K, Kendler DL, Kolanczyk M, Monsell F, Oetgen M, Richards BS, Schindeler A, Schorry EK, Wilkes D, Viskochil DH, Yang FC, Elefteriou F.

J Pediatr Orthop. 2013 Apr-May;33(3):269-75. doi: 10.1097/BPO.0b013e31828121b8. Review.

PMID:
23482262
17.

Trends in hip fracture rates in Canada: an age-period-cohort analysis.

Jean S, O'Donnell S, Lagacé C, Walsh P, Bancej C, Brown JP, Morin S, Papaioannou A, Jaglal SB, Leslie WD; Osteoporosis Surveillance Expert Working Group.

J Bone Miner Res. 2013 Jun;28(6):1283-9. doi: 10.1002/jbmr.1863.

PMID:
23426882
18.

Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday.

McClung M, Harris ST, Miller PD, Bauer DC, Davison KS, Dian L, Hanley DA, Kendler DL, Yuen CK, Lewiecki EM.

Am J Med. 2013 Jan;126(1):13-20. doi: 10.1016/j.amjmed.2012.06.023. Epub 2012 Nov 20. Review.

PMID:
23177553
19.

A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density.

Orwoll E, Teglbjærg CS, Langdahl BL, Chapurlat R, Czerwinski E, Kendler DL, Reginster JY, Kivitz A, Lewiecki EM, Miller PD, Bolognese MA, McClung MR, Bone HG, Ljunggren Ö, Abrahamsen B, Gruntmanis U, Yang YC, Wagman RB, Siddhanti S, Grauer A, Hall JW, Boonen S.

J Clin Endocrinol Metab. 2012 Sep;97(9):3161-9. doi: 10.1210/jc.2012-1569. Epub 2012 Jun 21.

PMID:
22723310
20.

Skeletal histomorphometry in subjects on teriparatide or zoledronic acid therapy (SHOTZ) study: a randomized controlled trial.

Dempster DW, Zhou H, Recker RR, Brown JP, Bolognese MA, Recknor CP, Kendler DL, Lewiecki EM, Hanley DA, Rao DS, Miller PD, Woodson GC 3rd, Lindsay R, Binkley N, Wan X, Ruff VA, Janos B, Taylor KA.

J Clin Endocrinol Metab. 2012 Aug;97(8):2799-808. doi: 10.1210/jc.2012-1262. Epub 2012 Jun 14.

PMID:
22701017
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk